Cencora CFO Retirement Announced, Financial Guidance Reaffirmed
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cencora ( (COR) ) has provided an announcement.
Cencora, Inc., a leading global pharmaceutical solutions provider with more than $300 billion in annual revenue, serves pharmaceutical innovators and care providers by optimizing market access and ensuring secure delivery of drugs and healthcare products worldwide. The company is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, supported by over 51,000 employees focused on improving health outcomes.
On March 17, 2026, Cencora announced that Executive Vice President and Chief Financial Officer James F. Cleary, who has served as CFO since November 2018, will retire effective June 30, 2026, and remain as an adviser through year-end to support a smooth transition. The company has launched an internal and external search for his successor and simultaneously reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal 2026, signaling continuity in its financial outlook despite the leadership change.
The most recent analyst rating on (COR) stock is a Hold with a $384.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
The score is held back primarily by balance-sheet leverage and thin margins, partly offset by strong cash generation and a constructive earnings outlook with raised FY2026 guidance. Technicals are mildly supportive, while valuation appears demanding relative to the business model and dividend yield is modest.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora, Inc. is a leading global pharmaceutical solutions organization that partners with drug innovators across the value chain to improve market access to therapies for people and animals worldwide. The Fortune 500 company, ranked #10 in the U.S. and #18 globally, generates more than $300 billion in annual revenue by providing secure, reliable delivery of pharmaceuticals, healthcare products, and related solutions through its 51,000-plus employees.
Average Trading Volume: 1,179,052
Technical Sentiment Signal: Buy
Current Market Cap: $67.28B
For an in-depth examination of COR stock, go to TipRanks’ Overview page.
